Structure Therapeutics Reports Positive Phase 2 Data for Oral GLP-1 Agonist

Structure Therapeutics Inc. announced positive topline data from its Phase 2 clinical program for aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity. The Phase 2 ACCESS II study showed placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks, with no evidence of plateau. Continued weight loss was observed in the ACCESS Open Label Extension (OLE) study, with a 120 mg dose achieving 16.2% weight loss at 56 weeks. Interim data from body composition and OLE studies suggest improved tolerability with a lower 2.5 mg starting dose, resulting in significantly fewer adverse event-related discontinuations. Aleniglipron demonstrated a favorable safety profile across studies, with no cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation. The company is preparing for Phase 3 development, with an End-of-Phase 2 meeting with the FDA scheduled for Q2 2026 and Phase 3 initiation anticipated in 2H 2026. The data supports aleniglipron's potential as a best-in-class oral therapy for obesity.